From Insulin Innovations to Scandal" Novo Nordisk is a pharmaceutical powerhouse, dominating Europe as its largest company and producing life-saving insulin that millions depend on. But behind this ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

Novo also recently partnered with another biotech start-up, Septerna, to develop small molecules for weight loss and metabolic disorders. That collaboration is worth up to $2.2 billion between up ...

Investors were disappointed when Novo Nordisk A/S (NYSE:NVO)’s next-generation obesity medication, CagriSema, which was supposed to emerge in 2026, failed to achieve the weight loss goals they ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...

Novo Nordisk and Septerna plan to create new obesity pills that target G protein-coupled receptors (GPCRs), including GLP-1, GIP, and glucagon.

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.